MX2020009522A - Anticuerpos anti-folato del receptor 1 y usos de los mismos. - Google Patents
Anticuerpos anti-folato del receptor 1 y usos de los mismos.Info
- Publication number
- MX2020009522A MX2020009522A MX2020009522A MX2020009522A MX2020009522A MX 2020009522 A MX2020009522 A MX 2020009522A MX 2020009522 A MX2020009522 A MX 2020009522A MX 2020009522 A MX2020009522 A MX 2020009522A MX 2020009522 A MX2020009522 A MX 2020009522A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- receptor
- methods
- folate
- folate antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642213P | 2018-03-13 | 2018-03-13 | |
| PCT/US2019/021084 WO2019177854A1 (en) | 2018-03-13 | 2019-03-07 | Anti-folate receptor 1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009522A true MX2020009522A (es) | 2020-10-22 |
Family
ID=67906883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009522A MX2020009522A (es) | 2018-03-13 | 2019-03-07 | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11873335B2 (https=) |
| EP (1) | EP3765521A4 (https=) |
| JP (2) | JP7433236B2 (https=) |
| KR (1) | KR102808710B1 (https=) |
| CN (2) | CN111954681B (https=) |
| AU (1) | AU2019236091B2 (https=) |
| BR (1) | BR112020016469A2 (https=) |
| CA (1) | CA3091683A1 (https=) |
| EA (1) | EA202092125A1 (https=) |
| IL (1) | IL276949A (https=) |
| MX (1) | MX2020009522A (https=) |
| SG (1) | SG11202007494TA (https=) |
| WO (1) | WO2019177854A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| CA3160436A1 (en) * | 2019-12-17 | 2021-06-24 | Jack Chongyang LI | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof |
| TW202233684A (zh) * | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| CN115491358B (zh) * | 2021-06-17 | 2024-09-06 | 复星凯特生物科技有限公司 | 一种靶向b7-h3和folr1双打靶点car t的制备及应用 |
| CN116462768B (zh) * | 2023-06-13 | 2023-09-22 | 浙江时迈药业有限公司 | 针对folr1的双特异性抗体及其用途 |
| WO2025140416A1 (zh) * | 2023-12-28 | 2025-07-03 | 上海宏成药业有限公司 | 抗folr1特异性抗体的发明及应用 |
| WO2025161939A1 (en) * | 2024-01-31 | 2025-08-07 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Antibodies and uses thereof |
| CN118344485B (zh) * | 2024-06-18 | 2024-10-15 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| JP5059119B2 (ja) * | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗ｔｓｌｐ抗体 |
| WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
| FR2929946B1 (fr) * | 2008-04-11 | 2010-05-28 | Pf Medicament | Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer |
| US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
| TWI622402B (zh) * | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| CN103347537A (zh) | 2010-10-20 | 2013-10-09 | 莫弗泰克股份有限公司 | 抗叶酸受体α抗体糖型 |
| MX343607B (es) | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
| SI2731972T1 (en) | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| BR112014028306A2 (pt) | 2012-05-15 | 2018-04-17 | Morphotek, Inc. | métodos para tratamento de câncer gástrico. |
| US9200073B2 (en) | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US9207238B2 (en) | 2012-12-07 | 2015-12-08 | Kyowa Hakko Kirin Co., Ltd. | Anti-FOLR1 antibody |
| US9522196B2 (en) | 2012-12-25 | 2016-12-20 | Kagoshima University | Antibody recognizing folate receptors α and β |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| SG11201509043RA (en) | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| CA2914237A1 (en) | 2013-06-20 | 2014-12-24 | Morphotek, Inc. | Methods for treatment of ovarian cancer |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| PL3055332T3 (pl) | 2013-10-08 | 2020-02-28 | Immunogen, Inc. | Schematy dawkowania immunokoniugatu anty-FOLR1 |
| KR20160088930A (ko) | 2013-12-04 | 2016-07-26 | 이뮤노젠 아이엔씨 | 항체 생산용 조성물 및 항체 생성 방법 |
| US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
| KR102508023B1 (ko) | 2014-09-03 | 2023-03-10 | 이뮤노젠 아이엔씨 | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3283886B1 (en) | 2015-04-17 | 2020-01-15 | Eisai Inc. | Methods for treating lung cancer |
| CN116440279B (zh) | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| EP3526254A1 (en) | 2016-10-12 | 2019-08-21 | Sutro Biopharma, Inc. | Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies |
| EP3544999A1 (en) | 2016-11-23 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| US20180333503A1 (en) | 2017-05-16 | 2018-11-22 | Immunogen, Inc. | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations |
-
2019
- 2019-03-07 AU AU2019236091A patent/AU2019236091B2/en active Active
- 2019-03-07 KR KR1020207028499A patent/KR102808710B1/ko active Active
- 2019-03-07 EP EP19767635.6A patent/EP3765521A4/en active Pending
- 2019-03-07 JP JP2020548760A patent/JP7433236B2/ja active Active
- 2019-03-07 CN CN201980019246.4A patent/CN111954681B/zh active Active
- 2019-03-07 CN CN202211567226.0A patent/CN115925952A/zh active Pending
- 2019-03-07 EA EA202092125A patent/EA202092125A1/ru unknown
- 2019-03-07 BR BR112020016469-0A patent/BR112020016469A2/pt not_active IP Right Cessation
- 2019-03-07 MX MX2020009522A patent/MX2020009522A/es unknown
- 2019-03-07 CA CA3091683A patent/CA3091683A1/en active Pending
- 2019-03-07 SG SG11202007494TA patent/SG11202007494TA/en unknown
- 2019-03-07 WO PCT/US2019/021084 patent/WO2019177854A1/en not_active Ceased
- 2019-03-07 US US15/733,541 patent/US11873335B2/en active Active
-
2020
- 2020-08-26 IL IL276949A patent/IL276949A/en unknown
-
2024
- 2024-02-06 JP JP2024016283A patent/JP2024056787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019236091B2 (en) | 2025-06-05 |
| JP2024056787A (ja) | 2024-04-23 |
| CA3091683A1 (en) | 2019-09-19 |
| CN115925952A (zh) | 2023-04-07 |
| WO2019177854A1 (en) | 2019-09-19 |
| EP3765521A1 (en) | 2021-01-20 |
| CN111954681A (zh) | 2020-11-17 |
| KR102808710B1 (ko) | 2025-05-15 |
| US20210002363A1 (en) | 2021-01-07 |
| JP2021517459A (ja) | 2021-07-26 |
| IL276949A (en) | 2020-10-29 |
| SG11202007494TA (en) | 2020-09-29 |
| JP7433236B2 (ja) | 2024-02-19 |
| US11873335B2 (en) | 2024-01-16 |
| EP3765521A4 (en) | 2022-03-23 |
| BR112020016469A2 (pt) | 2020-12-15 |
| EA202092125A1 (ru) | 2020-12-15 |
| AU2019236091A1 (en) | 2020-09-03 |
| CN111954681B (zh) | 2022-12-06 |
| KR20200132900A (ko) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| MX2020001309A (es) | Anticuerpos anti-cd47 y sus usos. | |
| CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
| MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
| CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| DOP2021000229A (es) | Materiales y métodos para modular la inmunidad mediada por cédula t | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| MX375119B (es) | Anticuerpos contra tau y sus usos. | |
| CO2018010827A2 (es) | Anticuerpos anti-factor bb del complemento y usos de estos | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| DOP2022000218A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
| MX2022002437A (es) | Metodos para la produccion de arginasa humana recombinante 1 y sus usos. | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| UY39699A (es) | Anticuerpos anti-tau y usos de estos | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
| EA202191115A1 (ru) | Новые пиридазины | |
| EA202092123A1 (ru) | Антитела против клаудина 18.2 и их применения | |
| MX2021009767A (es) | Moleculas de union de fmcr y usos de las mismas. |